November 3, 2025
1 min read

Alvotech plant issues foil another FDA review, this time for Teva-partnered Simponi biosimilar

Patients hoping to get their hands on a cheaper copycat of Johnson & Johnson’s fading anti-inflammatory blockbuster Simponi may have to wait for a few months more, thanks to an FDA inspection this summer that has derailed a leading biosimilar application from partners Teva and Alvotech.

Leave a Reply

Your email address will not be published.

Previous Story

Ductal vs. lobular breast cancer: Symptoms, treatments, and more

Next Story

Trump administration says SNAP will be partially funded in November

Previous Story

Ductal vs. lobular breast cancer: Symptoms, treatments, and more

Next Story

Trump administration says SNAP will be partially funded in November

Latest from Blog

Go toTop